JP2008524117A - Ｆｖｉｉｉの特定部位の変更 - Google Patents
Ｆｖｉｉｉの特定部位の変更 Download PDFInfo
- Publication number
- JP2008524117A JP2008524117A JP2007541405A JP2007541405A JP2008524117A JP 2008524117 A JP2008524117 A JP 2008524117A JP 2007541405 A JP2007541405 A JP 2007541405A JP 2007541405 A JP2007541405 A JP 2007541405A JP 2008524117 A JP2008524117 A JP 2008524117A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- factor viii
- complex
- fviii
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title abstract description 20
- 102100026735 Coagulation factor VIII Human genes 0.000 title abstract description 11
- 230000008859 change Effects 0.000 title description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 143
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 125
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 95
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 95
- 229960000301 factor viii Drugs 0.000 claims abstract description 93
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 47
- 230000006320 pegylation Effects 0.000 claims description 122
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 107
- 229920001184 polypeptide Polymers 0.000 claims description 105
- 235000018417 cysteine Nutrition 0.000 claims description 84
- 230000027455 binding Effects 0.000 claims description 80
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 51
- 235000001014 amino acid Nutrition 0.000 claims description 32
- 239000003638 chemical reducing agent Substances 0.000 claims description 29
- 208000009292 Hemophilia A Diseases 0.000 claims description 27
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 208000031220 Hemophilia Diseases 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 15
- 239000004365 Protease Substances 0.000 claims description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 12
- 108020003175 receptors Proteins 0.000 claims description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 12
- 108010001831 LDL receptors Proteins 0.000 claims description 11
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims description 9
- 108090000054 Syndecan-2 Proteins 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 9
- 238000006731 degradation reaction Methods 0.000 claims description 9
- 239000002131 composite material Substances 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 102000000853 LDL receptors Human genes 0.000 claims description 5
- 150000001412 amines Chemical group 0.000 claims description 5
- 108010038082 heparin proteoglycan Proteins 0.000 claims description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 5
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 5
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 101800004937 Protein C Proteins 0.000 claims description 4
- 101800001700 Saposin-D Proteins 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229960000856 protein c Drugs 0.000 claims description 4
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 claims description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 3
- 102000016611 Proteoglycans Human genes 0.000 claims description 3
- 108010067787 Proteoglycans Proteins 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 3
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims description 2
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 108091016585 CD44 antigen Proteins 0.000 claims 1
- 102400000827 Saposin-D Human genes 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 abstract description 2
- 230000002947 procoagulating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 72
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 65
- 210000002381 plasma Anatomy 0.000 description 32
- 229920000642 polymer Polymers 0.000 description 27
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 25
- 108090000190 Thrombin Proteins 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 229960004072 thrombin Drugs 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 231100000350 mutagenesis Toxicity 0.000 description 17
- 230000007017 scission Effects 0.000 description 17
- 102100036537 von Willebrand factor Human genes 0.000 description 17
- 238000002703 mutagenesis Methods 0.000 description 16
- 238000010186 staining Methods 0.000 description 16
- 108010047303 von Willebrand Factor Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- ILLKMACMBHTSHP-UHFFFAOYSA-N tetradecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ILLKMACMBHTSHP-UHFFFAOYSA-N 0.000 description 15
- 229960001134 von willebrand factor Drugs 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 238000004949 mass spectrometry Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000035602 clotting Effects 0.000 description 12
- 238000009826 distribution Methods 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 201000003542 Factor VIII deficiency Diseases 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 102000057593 human F8 Human genes 0.000 description 9
- 108091006006 PEGylated Proteins Proteins 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 7
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 7
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 7
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108010014173 Factor X Proteins 0.000 description 6
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005714 functional activity Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 208000034693 Laceration Diseases 0.000 description 5
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- 239000003114 blood coagulation factor Substances 0.000 description 5
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 229960000900 human factor viii Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000002110 C2 domains Human genes 0.000 description 4
- 108050009459 C2 domains Proteins 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000010405 clearance mechanism Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 150000002019 disulfides Chemical class 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000604197 Homo sapiens Neuronatin Proteins 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 102100038816 Neuronatin Human genes 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- WGNIPWQCWPXQFL-UHFFFAOYSA-N [I].[Ba] Chemical compound [I].[Ba] WGNIPWQCWPXQFL-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- -1 but not limited to Polymers 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 238000007820 coagulation assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 2
- DHORSBRLGKJPFC-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DHORSBRLGKJPFC-UHFFFAOYSA-N 0.000 description 2
- NIELXDCPHZJHGM-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NIELXDCPHZJHGM-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 2
- 101000999322 Homo sapiens Putative insulin-like growth factor 2 antisense gene protein Proteins 0.000 description 2
- 101001073409 Homo sapiens Retrotransposon-derived protein PEG10 Proteins 0.000 description 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241001662443 Phemeranthus parviflorus Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100036485 Putative insulin-like growth factor 2 antisense gene protein Human genes 0.000 description 2
- 102100035844 Retrotransposon-derived protein PEG10 Human genes 0.000 description 2
- 102100035123 Retrotransposon-like protein 1 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YZUUTMGDONTGTN-UHFFFAOYSA-N nonaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCOCCOCCOCCO YZUUTMGDONTGTN-UHFFFAOYSA-N 0.000 description 2
- GLZWNFNQMJAZGY-UHFFFAOYSA-N octaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCOCCOCCO GLZWNFNQMJAZGY-UHFFFAOYSA-N 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229920013730 reactive polymer Polymers 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OWTQQPNDSWCHOV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO OWTQQPNDSWCHOV-UHFFFAOYSA-N 0.000 description 1
- ZHMUMDLGQBRJIW-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ZHMUMDLGQBRJIW-UHFFFAOYSA-N 0.000 description 1
- HZYUNBJZCPLWPR-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HZYUNBJZCPLWPR-UHFFFAOYSA-N 0.000 description 1
- IEXKUCOGQITOPO-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEXKUCOGQITOPO-UHFFFAOYSA-N 0.000 description 1
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000233001 Carios Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038460 Renal haemorrhage Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 201000003231 brachydactyly type D Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940052810 complex b Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- WRZXKWFJEFFURH-UHFFFAOYSA-N dodecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO WRZXKWFJEFFURH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000055276 human IL3 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000018592 inherited blood coagulation disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001869 matrix assisted laser desorption--ionisation mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 108010013773 recombinant FVIIa Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220039283 rs199473359 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000003107 structure activity relationship analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- PSVXZQVXSXSQRO-UHFFFAOYSA-N undecaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO PSVXZQVXSXSQRO-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62727704P | 2004-11-12 | 2004-11-12 | |
| PCT/US2005/041205 WO2006053299A2 (en) | 2004-11-12 | 2005-11-14 | Site-directed modification of fviii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012231926A Division JP6109523B2 (ja) | 2004-11-12 | 2012-10-19 | Ｆｖｉｉｉの特定部位の変更 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008524117A true JP2008524117A (ja) | 2008-07-10 |
| JP2008524117A5 JP2008524117A5 (enExample) | 2009-01-08 |
Family
ID=36337298
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541405A Pending JP2008524117A (ja) | 2004-11-12 | 2005-11-14 | Ｆｖｉｉｉの特定部位の変更 |
| JP2012231926A Expired - Lifetime JP6109523B2 (ja) | 2004-11-12 | 2012-10-19 | Ｆｖｉｉｉの特定部位の変更 |
| JP2015022993A Expired - Lifetime JP6018238B2 (ja) | 2004-11-12 | 2015-02-09 | Ｆｖｉｉｉの特定部位の変更 |
| JP2016234757A Expired - Fee Related JP6559642B2 (ja) | 2004-11-12 | 2016-12-02 | Ｆｖｉｉｉの特定部位の変更 |
| JP2016234756A Expired - Fee Related JP6487895B2 (ja) | 2004-11-12 | 2016-12-02 | Ｆｖｉｉｉの特定部位の変更 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012231926A Expired - Lifetime JP6109523B2 (ja) | 2004-11-12 | 2012-10-19 | Ｆｖｉｉｉの特定部位の変更 |
| JP2015022993A Expired - Lifetime JP6018238B2 (ja) | 2004-11-12 | 2015-02-09 | Ｆｖｉｉｉの特定部位の変更 |
| JP2016234757A Expired - Fee Related JP6559642B2 (ja) | 2004-11-12 | 2016-12-02 | Ｆｖｉｉｉの特定部位の変更 |
| JP2016234756A Expired - Fee Related JP6487895B2 (ja) | 2004-11-12 | 2016-12-02 | Ｆｖｉｉｉの特定部位の変更 |
Country Status (32)
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012505917A (ja) * | 2008-10-17 | 2012-03-08 | バクスター・インターナショナル・インコーポレイテッド | 低度の水溶性ポリマーを含む改変血液因子 |
| JP2012508172A (ja) * | 2008-11-03 | 2012-04-05 | バイエル・ヘルスケア・エルエルシー | 血友病の治療方法 |
| JP2013520441A (ja) * | 2010-02-21 | 2013-06-06 | バイエル・ヘルスケア・エルエルシー | 生体分子を活性化およびコンジュゲートする方法 |
| JP2013525414A (ja) * | 2010-04-30 | 2013-06-20 | カンタブ バイオファーマシューティカルズ パテンツ リミテッド | 共役血液凝固第ｖｉｉｉ因子 |
| JP2014520094A (ja) * | 2011-05-27 | 2014-08-21 | バクスター・インターナショナル・インコーポレイテッド | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2015509365A (ja) * | 2012-02-15 | 2015-03-30 | バイオジェン・アイデック・エムエイ・インコーポレイテ | 組換え第ｖｉｉｉ因子タンパク質 |
| JP2016518321A (ja) * | 2013-03-15 | 2016-06-23 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 組み換え因子ｖｉｉｉ配合物 |
| JP2016519120A (ja) * | 2013-04-28 | 2016-06-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 凝固因子タンパク質に対する免疫寛容を誘導するための組成物 |
| US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
| US12161696B2 (en) | 2016-12-02 | 2024-12-10 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| AU2005260763B2 (en) * | 2004-06-30 | 2011-12-22 | Nektar Therapeutics | Polymer-factor IX moiety conjugates |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| EP2586456B1 (en) | 2004-10-29 | 2016-01-20 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (FGF) |
| ES2633916T3 (es) | 2004-11-12 | 2017-09-26 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
| JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖ｐｅｇ化顆粒球コロニー刺激因子 |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| EP1893632B1 (en) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| RU2008145084A (ru) * | 2006-05-24 | 2010-06-27 | Ново Нордиск Хелс Кеа Аг (Ch) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| CN101557830B (zh) | 2006-12-15 | 2016-06-08 | 巴克斯特国际公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| AU2008237411B2 (en) | 2007-04-03 | 2013-10-03 | Ratiopharm Gmbh | Methods of treatment using glycopegylated G-CSF |
| WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
| KR20100095441A (ko) * | 2007-11-09 | 2010-08-30 | 백스터 인터내셔널 인코포레이티드 | 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법 |
| WO2009108806A1 (en) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Conjugated factor viii molecules |
| JP5997443B2 (ja) * | 2008-05-16 | 2016-09-28 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 標的化凝固因子およびそれを使用する方法 |
| KR20110017420A (ko) * | 2008-06-04 | 2011-02-21 | 바이엘 헬스케어 엘엘씨 | 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인 |
| ES2531464T3 (es) | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
| WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| WO2010060081A1 (en) * | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
| US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| WO2010102886A1 (en) * | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
| NZ595848A (en) * | 2009-03-20 | 2014-04-30 | Hanmi Science Co Ltd | Method for preparing a site-specific physiologically active polypeptide conjugate |
| JP5739865B2 (ja) * | 2009-03-24 | 2015-06-24 | バイエル・ヘルスケア・エルエルシー | 第ｖｉｉｉ因子変異体および使用の方法 |
| RU2595442C2 (ru) | 2009-07-27 | 2016-08-27 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN104530182A (zh) | 2009-07-27 | 2015-04-22 | 利普森技术有限公司 | 非凝血蛋白的糖基多唾液酸化 |
| US20120263701A1 (en) * | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
| DK2506868T3 (da) | 2009-12-06 | 2018-01-29 | Bioverativ Therapeutics Inc | Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー／エス | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| KR102416359B1 (ko) | 2010-04-15 | 2022-07-01 | 코디악 사이언시스 인코포레이티드 | 고분자량 쌍성이온-함유 중합체 |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| MY165089A (en) * | 2010-11-05 | 2018-02-28 | Baxalta Inc | A new variant of antihemophilic factor viii having increased specific activity |
| KR20130125789A (ko) * | 2010-12-16 | 2013-11-19 | 노보 노르디스크 에이/에스 | 수성 인자ⅷ 용액 |
| BR112013015898A2 (pt) | 2010-12-22 | 2018-06-26 | Baxter International Inc. | derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada. |
| HUE043894T2 (hu) | 2011-06-10 | 2019-09-30 | Bioverativ Therapeutics Inc | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei |
| WO2013004607A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| PL3513804T3 (pl) | 2011-07-08 | 2022-07-11 | Bioverativ Therapeutics Inc. | Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania |
| CN104093735B (zh) | 2011-09-23 | 2018-07-06 | 诺沃—诺迪斯克有限公司 | 新的胰高血糖素类似物 |
| KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| MX369862B (es) | 2012-02-15 | 2019-11-25 | Bioverativ Therapeutics Inc | Composiciones del factor viii y metodos para hacerlas y usarlas. |
| ES2651523T3 (es) | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| EP2666782A1 (en) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| EP2908847B1 (en) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| EP2914293A4 (en) | 2012-10-30 | 2016-04-20 | Biogen Ma Inc | METHOD OF USE OF FVIII POLYPEPTIDE |
| UY35463A (es) | 2013-03-15 | 2014-10-31 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix. |
| PL3666283T3 (pl) | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
| WO2015023894A1 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| PL3041513T3 (pl) | 2013-09-08 | 2021-01-25 | Kodiak Sciences Inc. | Obojnaczojonowe polimerowe koniugaty czynnika viii |
| MX2016005333A (es) * | 2013-10-22 | 2017-02-15 | Dbv Tech | Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos. |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
| US10325687B2 (en) | 2013-12-06 | 2019-06-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| US10822393B2 (en) | 2014-01-20 | 2020-11-03 | Octapharma Ag | Process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII/AG |
| WO2015120056A1 (en) | 2014-02-04 | 2015-08-13 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| SG10201913735SA (en) | 2014-03-24 | 2020-03-30 | Bioverativ Therapeutics Inc | Lyophilized factor ix formulations |
| US11181534B2 (en) * | 2014-04-04 | 2021-11-23 | Bloodworks | Routine laboratory and point-of-care (POC) testing for hemostasis |
| KR20160144429A (ko) | 2014-04-10 | 2016-12-16 | 바이엘 헬쓰케어 엘엘씨 | 배합된 배지 분말 제형 및 세포 배양을 위한 액체 배지의 제조 방법 |
| EP3151852A1 (en) | 2014-06-04 | 2017-04-12 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| WO2016000039A1 (en) | 2014-07-02 | 2016-01-07 | Csl Limited | Modified von willebrand factor |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
| EP3297656B1 (en) | 2015-05-22 | 2020-01-08 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
| CA2994547A1 (en) | 2015-08-03 | 2017-02-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| KR20180094114A (ko) | 2016-01-07 | 2018-08-22 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 돌연변이된 절단된 폰 빌레브란트 인자 |
| WO2017117630A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated von willebrand factor |
| WO2017222330A1 (ko) * | 2016-06-24 | 2017-12-28 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
| AU2017358865A1 (en) | 2016-11-11 | 2019-05-09 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
| AU2017360979A1 (en) | 2016-11-16 | 2019-05-30 | Bayer Healthcare Llc | Red blood cell targeted factor VIII and method of using the same |
| US12257288B2 (en) | 2016-12-02 | 2025-03-25 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| CA3051862A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| EP3816181A4 (en) | 2018-05-18 | 2022-04-20 | Zhengzhou Gensciences Inc. | Improved fviii fusion protein and use thereof |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
| WO2021113800A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513378A (ja) * | 1995-09-29 | 1999-11-16 | フアーマシア・アンド・アツプジヨン・アー・ベー | ポリペプチドと生体適合性ポリマーとのコンジュゲート |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| EP0294910B1 (en) | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| SK282483B6 (sk) | 1992-10-02 | 2002-02-05 | Genetics Institute, Inc. | Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| JPH09504174A (ja) | 1993-10-29 | 1997-04-28 | インサイト ファーマシューティカルズ，インク． | プロテアーゼネキシン１変異体を含むキメラ蛋白 |
| IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
| WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
| AU691111B2 (en) * | 1995-06-21 | 1998-05-07 | Google Technology Holdings LLC | Method and antenna for providing an omnidirectional pattern |
| WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| CN100471521C (zh) * | 1996-08-02 | 2009-03-25 | 奥索·麦克尼尔药品公司 | 含有与n-末端共价结合的单个水溶性聚合物的多肽类 |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
| DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| CN1113656C (zh) * | 1997-10-17 | 2003-07-09 | 丰收技术股份有限公司 | 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物 |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| ATE283034T1 (de) | 1998-04-27 | 2004-12-15 | Opperbas Holding Bv | Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen |
| US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| DE59914490D1 (de) | 1998-11-10 | 2007-10-18 | Sanquin Bloedvoorziening | Ein faktor viii-polypeptid mit faktor viii:c-aktivität |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| WO2000071714A2 (en) | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| EP1319016A4 (en) | 2000-09-19 | 2006-05-10 | Univ Emory | MODIFIED FACTOR VIII |
| CA2434097A1 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| PL371800A1 (en) * | 2001-03-22 | 2005-06-27 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| WO2002098454A2 (en) | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| JP4634036B2 (ja) | 2001-10-05 | 2011-02-16 | エクスプレッション セラピューティクス， エルエルシー | 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法 |
| WO2003087161A1 (en) | 2002-04-18 | 2003-10-23 | Merck Patent Gmbh | Modified factor viii |
| US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| WO2004060966A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| MXPA05007348A (es) | 2003-01-06 | 2005-10-05 | Nektar Therapeutics Al Corp | Derivados de polimeros solubles en agua tiol-selectivos. |
| WO2004075923A2 (en) | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| ATE478093T1 (de) | 2003-05-12 | 2010-09-15 | Affymax Inc | Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen |
| CN1747748B (zh) | 2003-05-23 | 2011-01-19 | 尼克塔治疗公司 | 具有特定原子排列的聚合物衍生物 |
| EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| EP1682106A4 (en) | 2003-10-30 | 2008-06-11 | Univ Emory | MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| DE602004026474D1 (de) | 2003-12-03 | 2010-05-20 | Univ Rochester | Rekombinanter faktor viii mit erhöhter spezifischer aktivität |
| WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
| ES2633916T3 (es) | 2004-11-12 | 2017-09-26 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
| EP1871801A2 (en) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
| JP2009532351A (ja) | 2006-03-31 | 2009-09-10 | バクスター・インターナショナル・インコーポレイテッド | ペグ化第ｖｉｉｉ因子 |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
-
2005
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es not_active Expired - Lifetime
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es not_active Expired - Lifetime
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh not_active Expired - Lifetime
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Ceased
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh not_active Expired - Lifetime
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en not_active Expired - Lifetime
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en not_active IP Right Cessation
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en not_active Expired - Lifetime
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en not_active Expired
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko not_active Expired - Fee Related
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko not_active Expired - Lifetime
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko not_active Expired - Fee Related
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es not_active Expired - Lifetime
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en not_active Ceased
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en not_active Expired - Lifetime
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 CA CA2586379A patent/CA2586379C/en not_active Expired - Lifetime
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh not_active Expired - Fee Related
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es not_active Expired - Lifetime
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr not_active IP Right Cessation
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko not_active Expired - Fee Related
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en not_active Expired - Lifetime
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh not_active Expired - Lifetime
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Ceased
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko not_active Expired - Lifetime
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 HR HRP20070268AA patent/HRP20070268B1/hr not_active IP Right Cessation
- 2005-11-14 MX MX2017007144A patent/MX392760B/es unknown
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en not_active Expired - Lifetime
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en not_active Expired - Lifetime
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en not_active Expired - Lifetime
-
2014
- 2014-02-12 PH PH12014500352A patent/PH12014500352B1/en unknown
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja not_active Expired - Lifetime
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja not_active Expired - Fee Related
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 BE BE2019C523C patent/BE2019C523I2/nl unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I2/el unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11513378A (ja) * | 1995-09-29 | 1999-11-16 | フアーマシア・アンド・アツプジヨン・アー・ベー | ポリペプチドと生体適合性ポリマーとのコンジュゲート |
Non-Patent Citations (3)
| Title |
|---|
| JPN6011030740; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ， ｖｏｌ． ９７， ｐａｇｅｓ ８５４８-８５５３ （２０００） * |
| JPN6011030743; Ｐｒｏｔｅｉｎ Ｅｎｇ．， ｖｏｌ． １６， ｐａｇｅｓ ７６１-７７０ （２００３） * |
| JPN6011030746; Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， ｖｏｌ． ２６９， ｐａｇｅｓ １３３９８-１３４０４ （１９９４） * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012505917A (ja) * | 2008-10-17 | 2012-03-08 | バクスター・インターナショナル・インコーポレイテッド | 低度の水溶性ポリマーを含む改変血液因子 |
| JP2012508172A (ja) * | 2008-11-03 | 2012-04-05 | バイエル・ヘルスケア・エルエルシー | 血友病の治療方法 |
| JP2013520441A (ja) * | 2010-02-21 | 2013-06-06 | バイエル・ヘルスケア・エルエルシー | 生体分子を活性化およびコンジュゲートする方法 |
| JP2013525414A (ja) * | 2010-04-30 | 2013-06-20 | カンタブ バイオファーマシューティカルズ パテンツ リミテッド | 共役血液凝固第ｖｉｉｉ因子 |
| JP2018162293A (ja) * | 2011-05-27 | 2018-10-18 | バクスアルタ ゲーエムベーハー | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2017206513A (ja) * | 2011-05-27 | 2017-11-24 | バクスアルタ ゲーエムベーハー | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2014520094A (ja) * | 2011-05-27 | 2014-08-21 | バクスター・インターナショナル・インコーポレイテッド | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2020059717A (ja) * | 2011-05-27 | 2020-04-16 | バクスアルタ ゲーエムベーハー | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2021183636A (ja) * | 2011-05-27 | 2021-12-02 | バクスアルタ ゲーエムベーハー | 増加した半減期を有する治療用タンパク質およびそれを調製する方法 |
| JP2015509365A (ja) * | 2012-02-15 | 2015-03-30 | バイオジェン・アイデック・エムエイ・インコーポレイテ | 組換え第ｖｉｉｉ因子タンパク質 |
| JP2016518321A (ja) * | 2013-03-15 | 2016-06-23 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 組み換え因子ｖｉｉｉ配合物 |
| JP2016519120A (ja) * | 2013-04-28 | 2016-06-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 凝固因子タンパク質に対する免疫寛容を誘導するための組成物 |
| US12161696B2 (en) | 2016-12-02 | 2024-12-10 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6487895B2 (ja) | Ｆｖｉｉｉの特定部位の変更 | |
| AU2012203813B2 (en) | Site-directed modification of FVIII | |
| AU2018267653A1 (en) | Site-directed modification of FVIII | |
| HK1218718B (zh) | Fviii的位点定向修饰 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081112 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081112 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111020 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111027 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111118 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120619 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121019 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121029 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20121116 |